# WILSON SONSINI

# Sonja R. Gerrard

ASSOCIATE

Litigation Seattle

sgerrard@wsgr.com 206-883-2649



# **FOCUS AREAS**

Life Sciences
Litigation
Patent Litigation
Post-Grant Review

# **EXPERIENCE**

Dr. Sonja Gerrard is an associate in the Seattle office of Wilson Sonsini Goodrich & Rosati, where her practice involves representing clients in proceedings before the Patent Trial and Appeal Board including *Inter Partes* Review. She has experience representing clients in the life sciences and medical device industries with a particular focus on second- and third-generation sequencing technologies.

Sonja has more than 20 years of scientific experience that includes positions in academia and the life sciences industry, as well as at the Centers for Disease Control and Prevention. Her areas of expertise include chemistry, biochemistry, molecular biology, diagnostics, and infectious diseases. Prior to joining the firm, she was an assistant professor at the University of Michigan. Her laboratory studied hemorrhagic fever viruses and created genetic systems for studying viral replication and development of recombinant vaccines. She also taught courses in general virology and diagnostic methods for detection of viruses.

# **CREDENTIALS**

### Education

- J.D., University of Washington School of Law
- Ph.D., Chemistry, University of Oregon
- B.S., Chemistry, University of California, Davis

#### Admissions

- State Bar of California
- State Bar of Washington
- U.S. Court of Appeals for the Federal Circuit
- U.S. Patent and Trademark Office

#### **MATTERS**

# **Select Matters**

- Forte Biosciences, Inc.\* v. University of Massachusetts (Post-Grant Review)
- TwinStrand Biosciences, Inc. v. Guardant Health, Inc.\*(Inter Partes Reviews)
- Guardant Health, Inc.\* v. University of Washington Through its Center for Commercialization (Inter Partes Reviews)
- Foundation Medicine, Inc. v. Guardant Health, Inc.\* (Inter Partes Reviews and CAFC)
- Alphatec Holdings, Inc. v. NuVasive, Inc.\* (Inter Partes Reviews, District Court, and CAFC)
- Moderna TX, Inc. v. Arbutus Biopharma Corporation\* (Inter Partes Reviews and CAFC)
- Personal Genome Diagnostics, Inc. v. Guardant Health, Inc.\* (Inter Partes Reviews)
- Forty Seven, Inc. \* v. Stichting Sanguin Bloedvoorziening et al. (Inter Partes Reviews)

## **INSIGHTS**

#### **Select Publications**

- Co-author, "PTAB Year in Review," Wilson Sonsini, 2017-Present
- Co-author, "USPTO Issues Second Round of AIA Rule Changes," Wilson Sonsini Alert, April 1, 2016
- Co-author, "Federal Circuit Ruling in Dell v. Acceleron Limits New Late-Stage Grounds of Challenge in America Invents Act Trials," Wilson Sonsini Alert, March 21, 2016
- Co-author with D.D. Raymond, M.E. Piper, G. Skiniotis, and J.L. Smith, "Phleboviruses encapsidate their genomes by sequestering RNA bases," 109(47) Proceedings of the National Academy of Sciences 19208-13, 2012
- Co-author with M.E. Piper and D.R. Sorenson, "Efficient cellular release of Rift Valley fever virus requires genomic RNA," 6(3) *PLoS One* e18070, 2011
- Co-author with D.D. Raymond, M.E. Piper, and J.L. Smith, "Structure of the Rift Valley fever virus nucleocapsid protein reveals a new architecture for RNA encapsidation," 107(26) *Proceedings of* the National Academy of Sciences 11769-74, 2010
- Co-author with V.M. Vaughn, C.C. Streeter, and D.J. Miller, "Restriction of Rift Valley fever virus virulence in mosquito cells," 2(2) *Viruses* 655-75, 2010